{"id":"NCT03551626","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes","officialTitle":"COMBI-APlus: Open-label, Phase IIIb Study of Dabrafenib in COMBInation With Trametinib in the Adjuvant Treatment of Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes of an Adapted Pyrexia AE-management Algorithm (Plus)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-29","primaryCompletion":"2020-10-05","completion":"2021-09-16","firstPosted":"2018-06-11","resultsPosted":"2024-03-18","lastUpdate":"2025-04-29"},"enrollment":552,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Malignant Melanoma"],"interventions":[{"type":"DRUG","name":"Dabrafenib","otherNames":["DRB436"]},{"type":"DRUG","name":"Trametinib","otherNames":["TMT212"]}],"arms":[{"label":"Dabrafenib and trametinib combination therapy","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study was to evaluate the impact on pyrexia-related outcomes of an adapted pyrexia adverse event (AE)-management algorithm, as well as safety, efficacy and health-related outcomes.","primaryOutcome":{"measure":"Composite Rate of Pyrexia Related Events","timeFrame":"Baseline up to 12 months","effectByArm":[{"arm":"Dabrafenib+Trametinib","deltaMin":7.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":100,"countries":["Argentina","Australia","Brazil","Canada","Czechia","Finland","France","Greece","Hungary","Israel","Italy","Japan","Latvia","Lithuania","Norway","Poland","Portugal","Russia","Slovakia","Slovenia","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35042070"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1189"]},"adverseEventsSummary":{"seriousAny":{"events":121,"n":552},"commonTop":["Pyrexia","Headache","Blood creatine phosphokinase increased","Diarrhoea","Chills"]}}